Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,789 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. Among authors: woodward m. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E. Honig LS, et al. Among authors: woodward m. N Engl J Med. 2018 Jan 25;378(4):321-330. doi: 10.1056/NEJMoa1705971. N Engl J Med. 2018. PMID: 29365294 Free article. Clinical Trial.
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, Cassetta E, Woodward M, Boada M, van Dyck CH, Grimmer T, Selkoe DJ, Schneider A, Blondeau K, Hu N, Quartino A, Clayton D, Dolton M, Dang Y, Ostaszewski B, Sanabria-Bohórquez SM, Rabbia M, Toth B, Eichenlaub U, Smith J, Honigberg LA, Doody RS. Ostrowitzki S, et al. Among authors: woodward m. JAMA Neurol. 2022 Nov 1;79(11):1113-1121. doi: 10.1001/jamaneurol.2022.2909. JAMA Neurol. 2022. PMID: 36121669 Free PMC article. Clinical Trial.
Differentiating the frontal variant of Alzheimer's disease.
Woodward M, Jacova C, Black SE, Kertesz A, Mackenzie IR, Feldman H; ACCORD investigator group. Woodward M, et al. Int J Geriatr Psychiatry. 2010 Jul;25(7):732-8. doi: 10.1002/gps.2415. Int J Geriatr Psychiatry. 2010. PMID: 19823987
Predictors of Mortality in Dementia: The PRIME Study.
Connors MH, Ames D, Boundy K, Clarnette R, Kurrle S, Mander A, Ward J, Woodward M, Brodaty H. Connors MH, et al. Among authors: woodward m. J Alzheimers Dis. 2016 Apr 12;52(3):967-74. doi: 10.3233/JAD-150946. J Alzheimers Dis. 2016. PMID: 27079702
Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.
Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB Jr, Bales K, Alvey C, McCush F, Yang J, Kupiec JW, Bednar MM. Landen JW, et al. Among authors: woodward m. Clin Neuropharmacol. 2013 Jan-Feb;36(1):14-23. doi: 10.1097/WNF.0b013e31827db49b. Clin Neuropharmacol. 2013. PMID: 23334070 Clinical Trial.
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O'Neil J, Evans RM, Harrigan P, Plassman BL, Burke JR, Wu J, Lutz MW, Haneline S, Schwarz AJ, Schneider LS, Yaffe K, Saunders AM, Ratti E; TOMMORROW study investigators. Burns DK, et al. Lancet Neurol. 2021 Jul;20(7):537-547. doi: 10.1016/S1474-4422(21)00043-0. Lancet Neurol. 2021. PMID: 34146512 Clinical Trial.
1,789 results